Amylin Pharmaceuticals, Inc. (AMLN) Release: SYMLIN® Use Helped Patients With Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range
6/11/2012 10:49:41 AM
PHILADELPHIA--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN®(pramlintide acetate) injection treatment was used along with insulin. Two abstracts highlighting the analyses evaluated the proportion of readings from self-monitored seven-point glucose profiles that fell above, below or within glycemic targets based on guidelines set by the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE). The data analyses are being presented at the 72nd Scientific Sessions of the ADA in Philadelphia.